1
Abraham J Domb, Ruxandra Gref, Yoshiharu Minamitake, Maria Teresa Peracchia, Robert S Langer: Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers. Massachusetts Institute of Technology, Arnall Golden & Gregory, December 28, 1999: US06007845 (332 worldwide citation)

Particles are provided that are not rapidly cleared from the blood stream by the macrophages of the reticuloendothelial system, and that can be modified to achieve variable release rates or to target specific cells or organs. The particles have a core of a multiblock copolymer formed by covalently l ...


2
Tatiana Borovac, Carole Neves, Maria Teresa Peracchia: Semi-solid formulations for the oral administration of taxoids. Aventis Pharma, Ross J Oehler, Aventis Pharmaceuticals, March 31, 2005: US20050070496-A1

The present invention relates to novel formulations of taxoids for oral administration. More particularly, this invention discloses and claims various semi-solid formulations for the oral administration of taxoids.


3
Maria Teresa Peracchia, Sophie Cote, Gilbert Gaudel: Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids. Aventis Pharma, Ross J Oehler, Aventis Pharmaceuticals, February 3, 2005: US20050025792-A1

The present invention relates to novel formulations of taxoids for oral administration. More particularly, the present invention discloses and claims self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids.


4

5

6
Maria Teresa PERACCHIA, Gilbert GAUDEL, Sophie COTE: Injectable or orally deliverable formulations of azetidine derivatives. Aventis Pharma, Andrea Q Ryan, Sanofi Aventis Us, October 18, 2007: US20070244085-A1

The invention concerns injectable or orally deliverable binary or ternary formulations of azetidine derivatives. The azetidine derivatives used in the inventive pharmaceutical compositions can be represented by the general formulae (Ia) or (Ib), wherein Ar is an aromatic or heteroaromatic group opti ...


7
Sophie Cote, Valerie Bobineau, Maria Teresa Peracchia: Pharmaceutical compositions based on azetidine derivatives. Finnegan Henderson Farabow Garrett & Dunner, July 24, 2003: US20030139386-A1

A stable pharmaceutical composition comprising at least one azetidine derivative of formula 1 in which Ar is an aromatic or heteroaromatic group optionally substituted with one or more (C1-C4)alkyl, halogen, NO2, CN, (C1-C4)alkoxy or OH groups, optionally in combination with one or more other active ...


8
Sophie Cote, Valerie Bobineau, Maria Teresa Peracchia: Pharmaceutical compositions based on azetidine derivatives. Aventis Pharma, Ross J Oehler, Aventis Pharmaceuticals, July 27, 2006: US20060166959-A1

A stable pharmaceutical composition comprising azetidine compound of formula (Ib): in a system comprising at most 2 principal excipients chosen from nonionic and hydrophilic surfactants capable of solubilizing the azetidine compound of formula (Ib) and, capable of causing the formation of a colloida ...


9
Maria Teresa PERACCHIA, Sophie COTE, Valerie BOBINEAU: Semi-solid systems containing azetidine derivatives. Aventis Pharma, Andrea Q Ryan, Sanofi Aventis Us, November 27, 2008: US20080293686-A1

The present invention relates to novel formulations of azetidine derivatives for oral administration comprising at least one azetidine compound of formula (Ia) or (Ib): in a system comprising a Vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate polymeric semi-solid material.


10
Sophie COTÉ, Valérie BOBINEAU, Maria Teresa PERACCHIA: Pharmaceutical compositions based on azetidine derivatives. Aventis Pharma, March 3, 2011: US20110053903-A1

A stable pharmaceutical composition comprising azetidine compound of formula (Ib): in a system comprising at most 2 principal excipients chosen from nonionic and hydrophilic surfactants capable of solubilizing the azetidine compound of formula (Ib) and, capable of causing the formation of a colloida ...